(MENAFN- GlobeNewsWire - Nasdaq) Opportunities center on AI-enabled signal detection, real-world evidence, outsourcing and emerging markets, driven by tighter regulation, rising R&D and post-market surveillance.Dublin, Sept. 14, 2026 (GLOBE NEWSWIRE) -- "Pharmacovigilance Market Report 2026" has been added to ResearchAndMarkets.com's offering.
Global Pharmacovigilance Market to Reach $17.41 Billion by 2030 as Drug Safety Investments Accelerate
The global pharmacovigilance market is experiencing rapid expansion as pharmaceutical companies, biotechnology businesses, healthcare organizations and regulators increase their focus on drug safety and patient outcomes. The market is projected to grow from $9.64 billion in 2025 to $10.86 billion in 2026, representing a compound annual growth rate (CAGR) of 12.7%. Historical growth has been supported by increased adverse drug reaction reporting, higher clinical trial volumes, expanding pharmaceutical approvals, wider use of chronic disease treatments and the establishment of international drug safety regulations.
Looking ahead, the pharmacovigilance market is forecast to reach $17.41 billion by 2030, expanding at a CAGR of 12.5%. Growth during the forecast period is expected to be driven by greater use of real-world data, rising approvals of biologics and biosimilars, the increasing complexity of combination therapies and the expansion of pharmacovigilance services in emerging markets. A stronger emphasis on measurable patient safety outcomes is also encouraging life sciences organizations to improve safety monitoring throughout the product lifecycle.
Key pharmacovigilance market trends include the expansion of post-marketing surveillance, growing adoption of real-world evidence for safety monitoring and increasing regulatory scrutiny. Pharmaceutical and biotechnology companies are also outsourcing more pharmacovigilance services to improve operational flexibility, access specialist expertise and manage complex reporting requirements. At the same time, integrated platforms that consolidate safety data from multiple sources are helping organizations strengthen signal detection, case management and regulatory compliance.
Increasing research and development activity is a major factor supporting pharmacovigilance market growth. Investment in pharmaceutical R&D enables companies to develop therapies with improved safety profiles while identifying potential risks during preclinical and clinical testing. Effective safety monitoring throughout development allows organizations to introduce risk-mitigation strategies earlier and prepare for post-marketing surveillance requirements. R&D investment also supports advances in adverse event monitoring, safety data analysis and signal detection technology. According to the UK Office for National Statistics, UK government net spending on R&D increased from £16.1 billion in 2022 to £17.4 billion in 2023, an increase of 8.2%.
Artificial intelligence is becoming increasingly important across the pharmacovigilance industry. AI-enabled systems can improve operational efficiency, support safety data management and accelerate the detection of potential safety signals. These capabilities allow organizations to process growing volumes of information while improving reporting accuracy and responsiveness. In August 2024, the Government of India launched Adverse Drug Reaction Monitoring System software to facilitate the collection and analysis of adverse events involving medicines and medical devices. The platform simplifies reporting for healthcare professionals and consumers, supports comprehensive safety data capture and strengthens regulatory compliance.
Strategic acquisitions are also reshaping the competitive landscape as businesses expand their end-to-end drug safety capabilities. In January 2023, AmerisourceBergen acquired Germany-based PharmaLex for an undisclosed amount. The transaction broadened AmerisourceBergen's ability to support pharmaceutical and biotechnology companies across the product lifecycle. PharmaLex provides pharmacovigilance systems, operations management and benefit-risk assessment services, enabling clients to enhance safety monitoring infrastructure and address increasingly complex regulatory obligations.
Demand for pharmacovigilance solutions spans case data management, signal detection, risk management and safety monitoring across preclinical development and Phase I through Phase IV clinical trials. Services may be managed internally or outsourced to specialist providers, depending on an organization's operational requirements, geographic reach and compliance strategy. Hospitals, pharmaceutical companies, biotechnology businesses and other healthcare organizations use these services to manage safety information and meet reporting obligations.
North America was the largest region in the pharmacovigilance market in 2025, supported by its established pharmaceutical industry, extensive clinical research activity and mature regulatory environment. Asia-Pacific is expected to be the fastest-growing region during the forecast period as clinical trials, pharmaceutical manufacturing and drug safety investments expand. Regions covered by the market include Asia-Pacific, Southeast Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. Countries covered include Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, the United Kingdom, the United States, Canada, Italy and Spain.
Markets Covered:
1) By Type: Spontaneous Reporting; Intensified ADR Reporting; Targeted Spontaneous Reporting; Cohort Event Monitoring; EHR Mining
2) By Service Provider: In-House; Contract Outsourcing
3) By Process Flow: Case Data Management; Signal Detection; Risk Management System
4) By Clinical Trial Phases: Preclinical; Phase I; Phase II; Phase III; Phase IV
5) By End User: Hospitals; Pharmaceutical Companies; Other End Users
Subsegments:
1) By Spontaneous Reporting: Individual Case Safety Reports (ICSRs); Voluntary Reporting Systems; Case Reports From Healthcare Professionals
2) By Intensified ADR Reporting: Active Surveillance Programs; Enhanced Monitoring In Clinical Trials; Risk Minimization Strategies
3) By Targeted Spontaneous Reporting: Reporting For Specific Drug Classes; Condition-Specific Reporting; Focused Surveillance Programs
4) By Cohort Event Monitoring: Prospective Cohort Studies; Retrospective Cohort Studies; Longitudinal Studies
5) By EHR Mining: Data Extraction From Electronic Health Records; Signal Detection Through EHR Analysis; Integration Of EHR Data With Pharmacovigilance Systems
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Key Attributes:
CONTACT:
CONTACT: ResearchAndMarkets.com
Laura Wood,Senior Press Manager...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Comments
No comment